Instructions for Authors 2017

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   - they do not fall within the journal's policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to AR.
   - plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online with Stanford University HighWire Press. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

---

### A Selection of Recent Articles

- **Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells.** M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (Spokane, WA; Duarte, CA, USA)
- **Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.** M. MEDINGER, C. LENGERKE, J. PASSWEG (Basel, Switzerland)
- **EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6 Expressing MDA-MB-231 Cells.** C. JOHNSON, B. SEGOVIA, R.P. KANDPAL (Pomona, CA, USA)
- **Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth.** N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (Los Angeles, CA; Boston, MA, USA; London, UK)
- **The Multiple Roles of Exosomes in Metastasis.** U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Basel, Switzerland)
- **High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (Vitis vinifera) in HeLa cells.** E.A. MAZZIO, K.F.A. SOLIMAN (Tallahassee, FL, USA)
- **Overexpression of HPV16 E6* Alters β-Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells.** W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (Loma Linda, CA, USA)
Exploration of the Radiotherapeutic Clinical Target Volume Delineation for Gastric Cancer from Lymph Node Metastases. W. DONG, B. LI, J. WANG, Y. SONG, Z. ZHANG, C. FU (Jinan; Yantai, PR China) ........................................ 4629

MR-guided Percutaneous Biopsy of Focal Hepatic Dome Lesions with Free-hand Combined with MR Fluoroscopy Using 1.0-T Open High-field Scanner. L. WANG, M. LIU, L. LIU, Y. ZHENG, Y. XU, X. HE, P. LI, C. LI (Jinan; Yantai; Liaocheng, PR China) .......................................................................................................................... 4635


Predictors of Malignancy for Female Patients with Suspicious Nipple Discharge: A Retrospective Study. L. JIN, L. ZHU, S. LI, Y. ZENG, L. HAIXIONG, F. SU, K. CHEN (Guangzhou, PR China) .......................................................... 4655

Preoperative High Neutrophil–to–Lymphocyte Ratio Is Associated with High-grade Bladder Cancer. X. TANG, S. WANG, C. AN, P. DU, Y. YANG (Beijing, PR China) .............................................................................................................................. 4659

Effects of Different Palliative Jaundice Reducing Methods on Immunologic Functions in Patients with Advanced Malignant Obstructive Jaundice. K. TANG, L.-L. SUI, G. XU, T. ZHANG, Q. LIU, X.-F. LIU (Yantai, PR China) .............................................................................................................................. 4665


Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis. Y. YANG, N. SUN, P. SUN, L. ZHANG (Yantai, PR China) ............... 4681

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer. W. WONG, P. SUN, Z. MU, J. LIU, C. YU, A. LIU (Jinan; Yantai, PR China) ................. 4687

Independent Correlation Between Ki67 Index and Circulating Tumor Cells in the Diagnosis of Colorectal Cancer. Y. YANG, J. LI, L. JIN, D. WANG, J. ZHANG, J. WANG, X. ZHAO, G. WU, H. YAO, Z. ZHANG (Beijing, PR China) .............................................................................................................................. 4693

Study of Preoperative Antiviral Treatment of Patients with HCC Negative for HBV-DNA. X.-F. LIU, T. ZHANG, K. TANG, L.-L. SUI, G. XU, Q. LIU (Yantai, PR China) .............................................................................................................................. 4701

Effect of Intervventional Therapy on the Expression of Survivin mRNA in Cervical Cancer. S.-G. WANG, N. MU, H.-Y. SUN (Yantai; Qingdao, PR China) .............................................................................................................................. 4707

Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases. Q. HE, X. BI, C. REN, Y. WANG, P. ZOU, H. ZHANG, N. CHI, C. XIU, Y. WANG, R. TAO (Yantai; Jinan, PR China) ....... 4711
Clinical Studies

Application of Localization and Needle Placement Guided by Mammographic, Ultrasound and Fiberoptic Ductoscopy for Resection of Non-palpable Breast Lesions. Z. YUAN, X. QU, Z.-T. ZHANG, W.G. JIANG (Beijing, PR China; Cardiff, UK) .......................................................... 4523


The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China. J. YE, W. WANG, L. XIN, S. OWEN, L. DUAN, Y. CHENG, H. ZHANG, S. ZHANG, T. LI, Y. LIU (Beijing; Datong, PR China; Cardiff, UK) ................................. 4549

Severe Cardiotoxicity in a Patient with Colorectal Cancer Treated with Bevacizumab. J. CHEN, F. DU, B. HU, C. CHI, H. CHU, L. JIANG, P. LI, Z. GONG (Yantai; Dalian, PR China) .......................................................... 4557

Application of Ultrasound-guided Core Needle Biopsy in the Diagnosis of T3 or T4 Stage Laryngeal and Hypopharyngeal Cancer. Y. WANG, D. LI, R. LIU, C. JIA, A. JIANG, Y. LV, S. DUAN, Y. CHENG, H. ZHANG, X. CAO, X. SONG (Yantai, PR China) ............................................................... 4563

Collision of Lymphoepithelioma-like Carcinoma with Diffuse Large B-cell Lymphoma of the Stomach: A Case Report. L.Y. LIU, H. ZHAO, L. SHENG, P. YANG, H. ZHOU, R. WANG (Jinan, Yantai, PR China) ......................... 4569


Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion. H. CHU, F. DU, Z. GONG, P. LIAN, Z. WANG, P. LI, B. HU, C. CHI, J. CHEN (Yantai; Dalian, PR China) ............................................................... 4587


Laparoscopic-assisted Transanal Total Mesorectal Excision for Middle–Low Rectal Carcinoma: A Clinical Study of 19 Cases. H.-W. YAO, G.-C. WU, Y.-C. YANG, L. JIN, Z.-P. ZHANG, N. CHEN, Z.-T. ZHANG (Beijing, PR China) ................................................................. 4599


Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma. P. LI, F. DU, Z. GONG, B. HU, C. CHI, H. CHU, J. CHEN (Yantai; Dalian, PR China) ............................................................... 4611

The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis. B. ZHOU, L. XU, J. YE, L. XIN, X. DUAN, Y. LIU (Beijing, PR China; Cardiff, UK) ................................................................. 4615

Comparison of Efficiency of Video Endoscopy and Open Inguinal Lymph Node Dissection. S. WANG, P. DU, X. TANG, C. AN, N. ZHANG, Y. YANG (Beijing, PR China) ............................................................... 4623

Contents continued on the preceding page
Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma. Q. ZHAO, D. KUN, B. HONG, X. DENG, S. GUO, X. TANG, Y. YANG, K. GONG, Q. LI, L. YE, W.G. JIANG, N. ZHANG (Beijing; Hami; Kelamayi; Taicang; Guangzhou, PR China; Cardiff, UK) ................................................................. 4379

Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro. Z. ZHAO, S. CHENG, C. ZABKIEWICZ, J. CHEN, L. ZHANG, L. YE, W.G. JIANG (Beijing, PR China; Cardiff, UK) .................................................................................................................. 4389


NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial–Mesenchymal Transition. F. YANG, Y. GU, Z. ZHAO, J. HUANG, W.G. JIANG, S. CHENG (Beijing, PR China; Cardiff, UK) ........... 4405

Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells. Y. CUI, B. WU, V. FLAMINI, B.A.J. EVANS, D. ZHOU, W.G. JIANG (Cardiff, UK; Beijing, PR China) ........ 4415

Puerarin Induces Hepatocellular Carcinoma Cell Apoptosis Modulated by MAPK Signaling Pathways in a Dose-dependent Manner. W.-G. ZHANG, X.-C. YIN, X.-F. LIU, K.-W. MENG, K. TANG, F.-L. HUANG, G. XU, J. GAO (Yantai; Weihai, PR China) .................................................................................................................. 4425

Synergistic Effects of SAM and Selenium Compounds on Proliferation, Migration and Adhesion of HeLa Cells. L. SUN, J. ZHANG, Q. YANG, Y. SI, Y. LIU, Q. WANG, F. HAN, Z. HUANG (Beijing, PR China) .......................................................... 4433

Cyclophilin A Is Overexpressed in Hepatocellular Carcinoma and Is Associated with the Cell Cycle. Z. GONG, C. CHI, X. HUANG, H. CHU, J. WANG, F. DU, L. JIANG, J. CHEN (Yantai; Weihai, PR China) .......................................................... 4443


Clinical Correlation Between WISP2 and β-Catenin in Gastric Cancer. L. LI, Y. CUI, J.F. JI, W.G. JIANG (Beijing, PR China; Cardiff, UK) ................................................................................................................. 4469

Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma. Z. GONG, Y. MU, J. CHEN, H. CHU, P. LIAN, C. WANG, J. WANG, L. JIANG (Yantai, PR China) ................................................................................................................. 4475


Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer. J. YIN, Y. CUI, L. LI, J. II, W.G. JIANG (Cardiff, UK; Beijing, PR China) ................................................................................................................. 4489

Reduced Expression of Metastasis Suppressor-1 (MTSS1) Accelerates Progression of Human Bladder Uroepithelium Cell Carcinoma. P. DU, S. WANG, X. TANG, C. AN, Y. YANG, W.G. JIANG (Beijing, PR China; Cardiff, UK) ................................................................................................................. 4499

Association of Intron Microsatellite Instability and Exon Mutational Profile of TP53 in Human Gastric Cancers. X. HUO, X. XIAO, S. ZHANG, D. ZHOU, Z. CHEN (Beijing, PR China) .................................................................................................................. 4507


Contents continued on the preceding page
Experimental Studies


Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment. A.D. SOBKOWICZ, A.J. SANDERS, M.D. MASON, W.G. JIANG (Cardiff, UK) .......................................................... 4255

Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelial–Mesenchymal Transition in Renal Cell Carcinoma In Vivo. Q. ZHAO, X. DENG, B. HONG, F. WANG, X. TANG, Y. YANG, K. GONG, L. YE, W.G. JIANG, N. ZHANG (Beijing; Xinjiang, PR China; Cardiff, UK) .......................................................... 4269

Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells. Z. YU, A.J. SANDERS, S. OWEN, S. CHENG, X. YANG, W.G. JIANG (Beijing, PR China; Cardiff, UK) .......................................................... 4277

Inhibition of Bevacizumab-induced Epithelial–Mesenchymal Transition by BATF2 Overexpression Involves the Suppression of Wnt/β-Catenin Signaling in Glioblastoma Cells. W. HUANG, C. ZHANG, M. CUI, J. NIU, W. DING (Beijing, PR China) .............................................................................. 4285

A Preclinical Study of Cell-seeded Tubularized Scaffolds Specially Secreting LL37 for Reconstruction of Long Urethral Defects. Y. LI, J. WU, F. FENG, C. MEN, D. YANG, Z. GAO, Z. ZHU, Y. CUI, H. ZHAO (Yantai, PR China; Cleveland, OH, USA) .............................................................................. 4295

GRP78 Participates in PCA3-regulated Prostate Cancer Progression. C. LIN, J. WANG, Y. WANG, P. ZHU, X. LIU, N. LI, J. LIU, L. YU, W. WANG (Yantai, PR China) .............................................................................. 4303

Immortalized Cancer-associated Fibroblasts Promote Prostate Cancer Carcinogenesis, Proliferation and Invasion. S. YU, Y. JIANG, F. WAN, J. WU, Z. GAO, D. LIU (Yantai, PR China) .............................................................................. 4311

Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer. V. FLAMINI, W.G. JIANG, Y. CUI (Cardiff, UK) .............................................................................. 4319

High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics. Z. LIU, G. LIANG, L. TAN, A. SU, W.G. JIANG, C. GONG (Guangzhou, PR China; Cardiff, UK).............................................................................. 4329

HIF1α-associated circDENND4C Promotes Proliferation of Breast Cancer Cells in Hypoxic Environment. G. LIANG, Z. LIU, L. TAN, A. SU, W.G. JIANG, C. GONG (Guangzhou, PR China; Cardiff, UK) .............................................................................. 4337


Ezrin-Radixin-Moesin Binding Phosphoprotein 50 (EBP50) Suppresses the Metastasis of Breast Cancer and HeLa Cells by Inhibiting Matrix Metalloproteinase-2 Activity. L. WANG, Y. QI, Y. XIONG, Z. PENG, Q. MA, Y. ZHANG, J. SONG, J. ZHENG (Beijing, PR China) .............................................................................. 4353

The Axis of CXCR4/SDF-1 Plays a Role in Colon Cancer Cell Adhesion Through Regulation of the AKT and IGF1R Signalling Pathways. F. ZHENG, Z. ZHANG, V. FLAMINI, W.G. JIANG, Y. CUI (Cardiff, UK; Beijing, PR China) .............................................................................. 4361

Comparison of Different Muscle-Relaxant Anesthetics on Growth, Migration and Invasion of Gastric Cancer Cells. A. JIANG, H. ZHAO, X. LIU, M. YU, J. CHEN, W.G. JIANG (Yantai, PR China; Cardiff, UK) .............................................................................. 4371
The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1+ to CD8+ Lymphocyte Ratio in Patients with Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, T. FUKUOKA, S. NAKAO, S. MATSUTANI, K. HIRAKAWA, M. OHIRA (Osaka, Japan) .......................................................... 4165

Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy. O. KLAPKO, E. GHOULAM, S. JAKATE, S. ESWARAN, L. USHA (Chicago, IL, USA) .................................................... 4173


Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test. K.C. ASCIUTTO, A.J. HENNINGSSON, H. BORGFELDT, L. DARLIN, C. BORGFELDT (Lund; Jönköping, Sweden) ................................................................................................................................................. 4183


Safety and Effectiveness of Laparoscopic Colorectal Resection in Elderly Patients with Colorectal Cancer: A Propensity Score Matching Study. A. ARIMOTO, H. HASEGAWA, H. SUGIYAMA, K. YAMASHITA, T. MATSUDA, M. TOMINAGA, Y. SUMI, S. SUZUKI, Y. KAKEJI (Kobe; Akashi, Japan) .......................... 4195

Early Gastric Cancer Exfoliating into Gastric Lavage (GL1 EGC) Shows a More Aggressive Behavior and Poorer Survival Compared to the Non-Exfoliative Counterpart (GL0 EGC). E. VIRGILIO, E. GIARNIERI, M.R. GIOVAGNOLI, M. MONTAGNINI, A. PROIETTI, R. D’URSO, P. MERCANTINI, G. BALDUCCI, M. CAVALINI (Rome, Italy) ................................................................................................................................ 4199

Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. T. GUILBAUD, O. TURRINI, C. LEMOINE, Y.P. LE TREUT, M. OUAISSI, V. MOUTARDIER, J.R. DELPERO (Marseille, France) ........................................................................................................ 4205

Utility of Inflammatory Marker- and Nutritional Status-based Prognostic Factors for Predicting the Prognosis of Stage IV Gastric Cancer Patients Undergoing Non-curative Surgery. K. MIMATSU, N. FUKINO, Y. OGASAWARA, Y. SAINO, T. OIDA (Kanagawa, Tokyo, Japan) ........................................................................................................ 4215


Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy. R. ARIYASU, A. HORIIKE, T. YOSHIZAWA, Y. DOTSU, J. KOYAMA, M. SAIKI, T. SONODA, S. NISHIKAWA, S. KITAZONO, N. YANAGITANI, M. NISHIO (Tokyo, Japan) ........................................................................................................ 4229

Total Glossectomy Without Laryngectomy for Advanced Squamous Cell Cancer of the Tongue: Functional and Oncological Results. M. REITER, U. HARRÉUS (Munich; Dusseldorf, Germany) ........................................................................................................ 4233


Contents continued on the preceding page
Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine–Benzoimidazole Structure. Y. SAWAGUCHI, R. YAMAZAKI, Y. NISHIYAMA, T. SASAI, M. MAE, A. ABE, T. YAEGASHI, H. NISHIYAMA, T. MATSUZAKI (Tokyo, Japan) ................................................................. 4051

Cyclooxygenase-2 Inhibition Enhances Proliferation of NKT Cells Derived from Patients with Laryngeal Cancer. J. KLATKA, E. GRYWALSKA, A. HYMOS, M. GUZ, K. POLBERG, J. ROLIŃSKI, A. STEPULAK (Lublin, Poland) .............................................................................................................................................. 4059


Nicotine Exposure Augments Renal Toxicity of 5-azacytidine Through p66shc: Prevention by Resveratrol. I. ARANY, S. HALL, A. FAISAL, M. DIXIT (Jackson, MS, USA; Lahore, Pakistan) ........................................ 4075


WNT/β-Catenin Signaling Inhibitor IC-2 Suppresses Sphere Formation and Sensitizes Colorectal Cancer Cells to 5-Fluorouracil. S. URUSHIBARA, T. TSUBOTA, R. ASAII, J. AZUMI, K. ASHIDA, Y. FUJIWARA, G. SHIOTA (Yonago, Japan) .............................................................................................................................................................................................................. 4085


Cell Cycle Arrest and Apoptosis Induced by Kinamycin F in Human Osteosarcoma Cells. A. BAVELLONI, E. FOCACCIA, M. PIAZZI, C. ERRANI, W. BLALOCK, I. FAENZA (Bologna, Italy) ........................................................................................................... 4103

Synergistic Effects of Arsenite on Radiosensitization of Glioblastoma Cells. Y. NINOMIYA, D. YU, E. SEKINE-SUZUKI, T. NAKAJIMA (Chiba, Japan; Soochow, PR China).......................................................................................................................... 4111


Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice via Inhibition of Gastrin-induced Anti-Apoptotic Effects. Y. SHIOMI, M. YOSHIMURA, K. KUKI, Y. HIRI, T. TANAKA (Kumagaya, Japan). 4127

Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose. Y. PARK, J.-Y. SON, B.-M. LEE, H.S. KIM, S. YOON (Suwon, Republic of Korea) ................................................................. 4139

Clinical Studies

Clinical Significance and Phenotype of MTA1 Expression in Esophageal Squamous Cell Carcinoma. H. HONJO, Y. TOH, M. SOHDA, S. SUZUKI, K. KAIRA, Y. KANAI, S. NAGAMORI, T. OYAMA, T. YOKOBORI, T. MIYAZAKI, H. KUWANO (Gunma; Fukuoka; Osaka, Japan) .......................................... 4147

Long-term Oncologic Outcomes of Robotic-assisted Radical Prostatectomy by a Single Surgeon. S.-C. HUNG, C.-K. YANG, C.-L. CHENG, Y.-C. OU (Taichung, Taiwan, ROC) ......................................................... 4157